NEDD9

Across TCGA pan-cancer cohorts, NEDD9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NEDD9 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher NEDD9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NEDD9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and UVM are the cancer types where NEDD9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.198	0.872	.003	12	view →
UCEC	DFS	Median	All	0.968	0.616	.007	10	view →
UVM	OS	Median	All	0.249	0.712	.033	6	view →
HNSC	OS	Median	All	0.453	0.770	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NEDD9–ESCA (OS)

Open the ESCA breakdown →